Home >> Research Area >>Metabolism>>PDE>> Rolipram

Rolipram

PDE4-inhibitor and an anti-inflammatory agent CAS# 61413-54-5

Rolipram

Catalog No. BCC2282----Order now to get a substantial discount!

Product Name & Size Price Stock
Rolipram: 5mg $23 In Stock
Rolipram: 10mg Please Inquire In Stock
Rolipram: 20mg Please Inquire Please Inquire
Rolipram: 50mg Please Inquire Please Inquire
Rolipram: 100mg Please Inquire Please Inquire
Rolipram: 200mg Please Inquire Please Inquire
Rolipram: 500mg Please Inquire Please Inquire
Rolipram: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Rolipram

Number of papers citing our products

Chemical structure

Rolipram

3D structure

Chemical Properties of Rolipram

Cas No. 61413-54-5 SDF Download SDF
PubChem ID 5092 Appearance Powder
Formula C16H21NO3 M.Wt 275.34
Type of Compound N/A Storage Desiccate at -20°C
Synonyms (R,S)-Rolipram; SB 95952; ZK 62711
Solubility DMSO : ≥ 41 mg/mL (148.91 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name 4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-one
SMILES COC1=C(C=C(C=C1)C2CC(=O)NC2)OC3CCCC3
Standard InChIKey HJORMJIFDVBMOB-UHFFFAOYSA-N
Standard InChI InChI=1S/C16H21NO3/c1-19-14-7-6-11(12-9-16(18)17-10-12)8-15(14)20-13-4-2-3-5-13/h6-8,12-13H,2-5,9-10H2,1H3,(H,17,18)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Rolipram

DescriptionSelective inhibitor of cAMP phosphodiesterase (PDE4) (IC50 = 2.0 μM). Discriminates between two conformational states of PDE4 isoenzymes. Separate isomers (R)-(-)-Rolipram and (S)-(+)-Rolipram are available.

Rolipram Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Rolipram Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Rolipram

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.6319 mL 18.1594 mL 36.3187 mL 72.6375 mL 90.7968 mL
5 mM 0.7264 mL 3.6319 mL 7.2637 mL 14.5275 mL 18.1594 mL
10 mM 0.3632 mL 1.8159 mL 3.6319 mL 7.2637 mL 9.0797 mL
50 mM 0.0726 mL 0.3632 mL 0.7264 mL 1.4527 mL 1.8159 mL
100 mM 0.0363 mL 0.1816 mL 0.3632 mL 0.7264 mL 0.908 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Rolipram

Rolipram is a PDE4-inhibitor and an anti-inflammatory agent.

Featured Products
New Products
 

References on Rolipram

PDE4 Inhibition by Rolipram Promotes Neuronal Differentiation in Human Bone Marrow Mesenchymal Stem Cells.[Pubmed:27459581]

Cell Reprogram. 2016 Aug;18(4):224-9.

Increased intracellular cyclic adenosine monophosphate (cAMP) can promote axonal elongation and facilitate neuronal repair, while decreased cAMP is associated with losses in neuronal regenerative capacity. Rolipram, which upregulates intracellular cAMP by blocking phosphodiesterase-4 (PDE4) enzyme activity, can mitigate diverse neurological disorders. In this study, we investigated whether Rolipram induces neuronal differentiation of human bone marrow-mesenchymal stem cells (hBM-MSCs). Rolipram-treated MSCs (Roli-MSCs) had significantly increased expression of the neuroprogenitor proteins Nestin, Musashi, GFAP, and Sox-2. When Roli-MSCs were differentiated with neuronal induction media (Roli-dMSCs), they exhibited cell body and dendritic morphologies similar to those of neurons. The neurite number and length of Roli-dMSCs were significantly increased compared to those of differentiated MSCs (dMSCs). Compared with undifferentiated hBM-MSCs, the Roli-dMSCs and dMSCs showed significantly increased expression of the neuronal-specific marker genes Nestin, Musashi, CD133, GFAP, NF-M, MAP-2, KCNH1, KCNH5, SCN3A, and CACNA1A, and decreased expression of other lineage-specific markers Adiponectin, ALP, FABP4, and MMP13. The Roli-dMSCs also showed a higher expression of the neuronal markers Nestin, Musashi, Sox-2, NF-M, and Tuj-1 compared to those of the undifferentiated hBM-MSCs, measured by immunocytochemistry and immunoblotting assay. Thus, we have shown that Rolipram ameliorates neuronal differentiation by the regulation of neuroprogenitor expression in hBM-MSCs, and Rolipram treatment of MSCs may improve the therapeutic efficacy of stem cell therapy for neurodegenerative disorders.

The Regulatory Role of Rolipram on Inflammatory Mediators and Cholinergic/Adrenergic Stimulation-Induced Signals in Isolated Primary Mouse Submandibular Gland Cells.[Pubmed:27143817]

Mediators Inflamm. 2016;2016:3745961.

Exposure to bacterial lipopolysaccharides (LPS) induces inflammatory signals in salivary glands. We investigated the regulatory role of phosphodiesterase 4 (PDE4) inhibitor Rolipram on inflammatory mediators and cholinergic/adrenergic stimulation-induced intracellular Ca(2+) signaling in salivary acinar and ductal cells. Submandibular gland (SMG) expressed PDE4A through 4D mRNA and PDE4 was localized in the luminal membrane of SMG. LPS induced Ca(2+) signaling and ROS production in SMG. Treatment with Rolipram blocked LPS-induced Ca(2+) increase and ROS production. The application of histamine evoked Ca(2+) signals and ROS production, which were attenuated by Rolipram in SMG cells. Moreover, LPS-induced NLRP3 inflammasome and cleaved caspase-1 were inhibited by Rolipram. The inhibitory role of Rolipram in ROS-induced Ca(2+) signaling was mainly observed in acinar cells and not in ductal cells. Rolipram also protected SMG acinar but not ductal cells from LPS-induced cell membrane damage. In the case of cholinergic/adrenergic stimulation, carbachol/isoproterenol-induced Ca(2+) signals were upregulated by the treatment of Rolipram in SMG. In the case of cAMP-dependent ductal bicarbonate secretion by Rolipram, no effect was observed on the modulation of ductal chloride/bicarbonate exchange activity. Rolipram could suppress the inflammatory signals and could be a potential therapeutic strategy against LPS-induced inflammation to protect the salivary gland cells.

Rolipram potentiates bevacizumab-induced cell death in human glioblastoma stem-like cells.[Pubmed:28202289]

Life Sci. 2017 Mar 15;173:11-19.

AIMS: Glioblastoma cancer stem-like cells (GCSCs) promote themselves proliferation by secreting the vascular endothelial growth factor A (VEGFA) in an autocrine manner, positively regulated by phosphodiesterase IV (PDE4). In the current study, we investigated the putative cytotoxic effect of bevacizumab, a VEGFA blocker, alone and in combination with a specific inhibitor of PDE4 called Rolipram on GCSCs isolated from human surgical tumor specimen with a focus on PI3K/AKT pathway. MAIN METHODS: CD133+/CD15+ GCSCs were characterized by flow cytometry and expanded in a serum-free primary culture system. The cell survival, apoptosis, and protein expression values were measured using MTT assay, TUNEL staining and western blot, successively. Intracellular cAMP and free secreted VEGFA levels were assessed by cAMP enzyme immunoassay and ELISA, respectively. KEY FINDINGS: Bevacizumab suppressed GCSCs survival with IC50~6.5mug/ml and enhanced the levels of apoptosis, p53 and cleaved-caspase3 along with a decrease in free VEGFA levels and ERKs activation. However, there was no significant modulation of AKT phosphorylation on serine 473, the intracellular PDE4A, VEGFA and cAMP levels. More cytotoxicity in co-treated cells coupled with a more substantial decline in the free VEGFA levels and a greater increase in the quantities of p53 and cleaved-caspase3 compared to those treated with bevacizumab alone. Co-treatment reduced phospho-AKT, endogenous VEGFA and PDE4A values but elevated cAMP levels. SIGNIFICANCE: This study highlighted a booster cytotoxic effect of combined Rolipram and bevacizumab treatment on the GCSCs primary culture, suggesting that this approach is warranted in treatment of GBMs overexpressing VEGFA and PDE4A.

The analgesic effect of rolipram is associated with the inhibition of the activation of the spinal astrocytic JNK/CCL2 pathway in bone cancer pain.[Pubmed:28025994]

Int J Mol Med. 2016 Nov;38(5):1433-1442.

Bone cancer pain (BCP) is one of the most difficult and intractable tasks for pain management, which is associated with spinal 'neuron-astrocytic' activation. The activation of the c-Jun N-terminal kinase (JNK)/chemokine (C-C motif) ligand (CCL2) signaling pathway has been reported to be critical for neuropathic pain. Rolipram (ROL), a selective phosphodiesterase 4 inhibitor, possesses potent anti-inflammatory and anti-nociceptive activities. The present study aimed to investigate whether the intrathecal administration of ROL has an analgesic effect on BCP in rats, and to assess whether the inhibition of spinal JNK/CCL2 pathway and astrocytic activation are involved in the analgesic effects of ROL. The analgesic effects of ROL were evaluated using the Von Frey and Hargreaves tests. Immunofluorescence staining was used to determine the number of c-Fos immunoreactive neurons, and the expression of spinal astrocytes and microglial activation on day 14 after tumor cell inoculation. Enzymelinked immunosorbent assay (ELISA) was used to detect the expression of pro-inflammatory cytokines [interleukin (IL)-1beta, IL-6 and tumor necrosis factor (TNF)-alpha] and chemokines (CCL2), and western blot analysis was then used to examine the spinal phosphodiesterase 4 (PDE4), ionized calcium binding adapter molecule-1 (IBA-1) and JNK levels on day 14 after tumor cell inoculation. The results revealed that ROL exerted a short-term analgesic effect in a dose-dependent manner, and consecutive daily injections of ROL exerted continuous analgesic effects. In addition, spinal 'neuronastrocytic' activation was suppressed and was associated with the downregulation of spinal IL-1beta, IL-6 and TNF-alpha expression, and the inhibition of PDE4B and JNK levels in the spine was also observed. In addition, the level of CCL2 was decreased in the rats with BCP. The JNK inhibitor, SP600125, decreased CCL2 expression and attenuated pain behavior. Following co-treatment with ROL and SP600125, no significant increases in thermal hyperalgesia and CCL2 expression were observed compared with the ROL group. Thus, our findings suggest that the analgesic effects of ROL in BCP are mainly mediated through the inhibition of 'neuronastrocytic' activation, which occurs via the suppression of spinal JNK/CCL2 signaling.

Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?[Pubmed:9184477]

Trends Pharmacol Sci. 1997 May;18(5):164-71.

Phosphodiesterase type 4 (PDE4) plays a major role in modulating the activity of virtually all cells involved in the inflammatory process. Inhibitors of this enzyme family display impressive anti-inflammatory and disease-modifying effects in a variety of experimental models. In this review, Mauro Teixeira, Robert Gristwood, Nicola Cooper and Paul Hellewell examine the capacity of PDE4 inhibitors to exert anti-inflammatory actions in vivo and discuss the potential of this class of drugs to take their place as novel therapeutic agents for a variety of inflammatory diseases.

Rolipram, a cyclic AMP-selective phosphodiesterase inhibitor, reduces neuronal damage following cerebral ischemia in the gerbil.[Pubmed:7713141]

Eur J Pharmacol. 1995 Jan 5;272(1):107-10.

We examined the effects of Rolipram, a cyclic AMP-selective phosphodiesterase inhibitor, on cerebral ischemia-induced neuronal damage in Mongolian gerbils. Transient forebrain ischemia was induced by 3-min occlusion of bilateral common carotid arteries. Rolipram, at a dose of 0.3 or 3 mg/kg, was injected i.p. 30 min before ischemia. Histopathological observations showed that neuronal damage to the hippocampal CA1 subfield, which was seen 7 days after ischemia in vehicle-treated animals, was reduced in animals treated with the higher dose of Rolipram.

Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behavior maintained by differential reinforcement of low response rate.[Pubmed:8383740]

J Pharmacol Exp Ther. 1993 Mar;264(3):1168-78.

Four inhibitors of cyclic AMP phosphodiesterase (PDE), Rolipram, Ro 20-1724, ICI 63,197 and CP 76,593, reduced response rates and increased reinforcement rates of rats under a differential reinforcement of low rate 72-sec schedule for water reinforcement in a dose-dependent manner. These actions of the PDE inhibitors are similar to those reported for proven antidepressant drugs. Administration of forskolin, which increases cyclic AMP levels by activation of the catalytic subunit of adenylyl cyclase, either i.p. or i.c.v. did not mimic the effects of the PDE inhibitors. The behavioral effects of the PDE inhibitors were not antagonized by the beta adrenergic antagonist propranolol, suggesting that these drugs were not altering behavior via an increase in norepinephrine release and an indirect stimulation of beta adrenergic receptors. 6-Hydroxydopamine-induced lesions of noradrenergic neurons increased sensitivity to Rolipram. This suggests that alterations in PDE activity with a concomitant increase in sensitivity to PDE inhibitors may occur subsequent to functional denervation.

Description

Rolipram is a selective phosphodiesterases PDE4 inhibitor with IC50s of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively.

Keywords:

Rolipram,61413-54-5,(R,S)-Rolipram; SB 95952; ZK 62711,Natural Products,PDE, buy Rolipram , Rolipram supplier , purchase Rolipram , Rolipram cost , Rolipram manufacturer , order Rolipram , high purity Rolipram

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: